These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 26328624

  • 1. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 2. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.
    Clin Ther; 2013 Sep 02; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [Abstract] [Full Text] [Related]

  • 3. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014 Sep 02; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 4. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM.
    J Clin Lipidol; 2016 Sep 02; 10(6):1442-1451.e4. PubMed ID: 27919362
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 02; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 6. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K, Koshizaka M, Tokuyama H, Tokuyama T, Ishikawa T, Maezawa Y, Takemoto M, Yokote K.
    Lipids Health Dis; 2018 Mar 15; 17(1):51. PubMed ID: 29544483
    [Abstract] [Full Text] [Related]

  • 7. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Mar 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 8. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 9. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.
    J Clin Lipidol; 2012 Aug 15; 6(6):565-72. PubMed ID: 23312052
    [Abstract] [Full Text] [Related]

  • 10. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
    Stroes ESG, Susekov AV, de Bruin TWA, Kvarnström M, Yang H, Davidson MH.
    J Clin Lipidol; 2018 Aug 15; 12(2):321-330. PubMed ID: 29289538
    [Abstract] [Full Text] [Related]

  • 11. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
    Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
    J Clin Lipidol; 2009 Oct 15; 3(5):332-40. PubMed ID: 21291831
    [Abstract] [Full Text] [Related]

  • 12. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE.
    JAMA; 2020 Dec 08; 324(22):2268-2280. PubMed ID: 33190147
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2012 Oct 01; 110(7):984-92. PubMed ID: 22819432
    [Abstract] [Full Text] [Related]

  • 14. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT, Soni PN, Juliano RA.
    J Clin Lipidol; 2015 Oct 01; 9(3):377-83. PubMed ID: 26073397
    [Abstract] [Full Text] [Related]

  • 15. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G, Mushtaq S.
    Lipids Health Dis; 2022 Sep 01; 21(1):84. PubMed ID: 36050695
    [Abstract] [Full Text] [Related]

  • 16. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL, Gaudet D, Davidson M, Rensfeldt M, Yang H, Nilsson C, Kvarnström M, Oscarsson J.
    Lipids Health Dis; 2020 May 30; 19(1):117. PubMed ID: 32473640
    [Abstract] [Full Text] [Related]

  • 17. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb 30; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 18. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT, Juliano RA, Philip S.
    Am J Cardiol; 2019 Sep 01; 124(5):696-701. PubMed ID: 31277790
    [Abstract] [Full Text] [Related]

  • 19. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia.
    Blair HA, Dhillon S.
    Am J Cardiovasc Drugs; 2014 Oct 01; 14(5):393-400. PubMed ID: 25234378
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
    Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez-Briones I, Gonzalez JG, Ocampo R, Sanchez-Mijangos H, Bernal-Rosales LP, Polanco A.
    Curr Med Res Opin; 2013 Apr 01; 29(4):379-86. PubMed ID: 23323877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.